Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | Mogamulizumab |
Trade Name | Poteligeo |
Synonyms | KW-0761|Mogamulizumab-kpkc |
Drug Descriptions |
Poteligeo (mogamulizumab-kpkc) is a monoclonal antibody that binds to and inhibits C-C chemokine receptor 4 (CCR4) signaling, which leads to inhibition of Tregs and enhancement of host antitumor immunity (PMID: 25496334). Poteligeo (mogamulizumab-kpkc) is FDA approved for adult patients with relapsed or refractory mycosis fungoides or Sezary syndrome (FDA.gov). |
DrugClasses | |
CAS Registry Number | 1159266-37-1 |
NCIT ID | C62510 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Durvalumab + Mogamulizumab | Durvalumab Mogamulizumab | 0 | 0 |
Hu5F9-G4 + Mogamulizumab | Hu5F9-G4 Mogamulizumab | 0 | 1 |
KHK2455 + Mogamulizumab | KHK2455 Mogamulizumab | 0 | 1 |
Mogamulizumab | Mogamulizumab | 0 | 7 |
Mogamulizumab + Nivolumab | Mogamulizumab Nivolumab | 0 | 1 |
Mogamulizumab + Pembrolizumab | Mogamulizumab Pembrolizumab | 0 | 1 |
Mogamulizumab + rhIL-15 | Mogamulizumab rhIL-15 | 0 | 1 |
Mogamulizumab + Tremelimumab | Mogamulizumab Tremelimumab | 0 | 0 |
Mogamulizumab + Utomilumab | Mogamulizumab Utomilumab | 0 | 1 |